ニンテダニブエタンスルホン酸塩
ニンテダニブエタンスルホン酸塩 物理性質
- 融点 :
- >233°C (dec.)
- 貯蔵温度 :
- -20°C Freezer
- 溶解性:
- DMSO(微量)、メタノール(微量)
- 外見 :
- 黄色の固体。
- 色:
- 薄黄色~黄色
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
絵表示(GHS) |
|
注意喚起語 |
警告 |
危険有害性情報 |
コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
![](/GHS07.jpg) |
P264, P270, P301+P312, P330, P501 |
H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
![](/GHS07.jpg) |
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
![](/GHS07.jpg) |
P264, P280, P305+P351+P338,P337+P313P |
H335 |
呼吸器への刺激のおそれ |
特定標的臓器毒性、単回暴露; 気道刺激性 |
3 |
警告 |
![](/GHS07.jpg) |
|
|
注意書き |
P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
P305+P351+P338 |
眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
ニンテダニブエタンスルホン酸塩 価格
もっと(5)
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-5714 |
(3Z)-2,3-Dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1h-indole-6-carboxylic acid methyl ester ethanesulfonate |
656247-18-6 |
100mg |
¥147600 |
2018-12-26 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01FLC519772 |
Nintedanib, Ethanesulfonate Salt
Nintedanib Ethanesulfonate Salt |
656247-18-6 |
1g |
¥323400 |
2018-12-26 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
SML3780 |
Nintedanib ethanesulphonate ≥98% (HPLC)
≥98% (HPLC) |
656247-18-6 |
5mg |
¥12700 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
SML3780 |
Nintedanib ethanesulphonate ≥98% (HPLC)
≥98% (HPLC) |
656247-18-6 |
25mg |
¥51100 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01FLC519772 |
Nintedanib, Ethanesulfonate Salt
Nintedanib Ethanesulfonate Salt |
656247-18-6 |
2g |
¥580800 |
2018-12-26 |
購入 |
ニンテダニブエタンスルホン酸塩 化学特性,用途語,生産方法
効能
抗線維化薬, チロシンキナーゼ阻害薬
商品名
オフェブ (日本ベーリンガーインゲルハイム)
説明
Nintedanib esylate is a potent, oral triple angiokinase inhibitor
developed by Boehringer Ingelheim that targets proangiogenic and
pro-fibrotic pathways mediated by the vascular endothelial growth
factor receptor, fibroblast growth factor receptor and plateletderived
growth factor receptor families, as well as Src and Flt-3
kinases. It was approved for the treatment of idiopathic pulmonary
fibrosis (IPF), a condition in which the lungs become progressively
scarred over time, by the US FDA in October 2014 and by
the EMA in January 2015. The FDA granted nintedanib esylate
fast-track, priority review, orphan product, and breakthrough
designations. The drug was also approved by the EMA in November
2014 for treatment of non-small cell lung cancer in combination
with docetaxel after first-line chemotherapy.
使用
Nintedanib Esylate is the salt form of Nintedanib, which is angiokinase inhibitor and is used in the treatment of idiopathic pulmonary fibrosis. Also inhibits the process blood vessel formation which may be used to assist in cancer therapy.
定義
ChEBI: An organosulfonate salt obtained by combining nintedanib with one molar equivalent of ethanesulfonic acid. A kinase inhibitor used for the treatment of idiopathic pulmonary fibrosis and cancer.
Properties and Applications
Nintedanib esylate (NE) is used in the treatment of idiopathic pulmonary fibrosis (IPF) and in diverse cancers, including nonsmall cell lung cancer (NSCLC). NE has a pH-dependent solubility profile with low aqueous solubility under neutral pH and increased solubility at acidic pH. The oral bioavailability of NE is 4.7% because it is a P-gp substrate and also undergoes first-pass metabolism in the liver by esterases. However, the administration of NE along with food increases the area under the curve (AUC) and maximum concentration (Cmax) when the drug is taken with food; hence, it has a positive food effect[1].
ニンテダニブエタンスルホン酸塩 上流と下流の製品情報
原材料
準備製品
ニンテダニブエタンスルホン酸塩 生産企業
Global( 309)Suppliers
ニンテダニブエタンスルホン酸塩 スペクトルデータ(1HNMR)
656247-18-6(ニンテダニブエタンスルホン酸塩)キーワード:
- 656247-18-6
- (3Z)-2,3-Dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester ethanesulfonate
- BIBF 1120 esylate
- BIBF-1120 esylate
- BIBF1120/nintedanib ethanesulfonate salt
- Trinidad Neeb esylate
- Intedanib ethanesulfonate
- Nintedanib ethanesulfonate salt
- Trinidad Neeb ethanesulfonate
- Nintedanib(ethanesulfonic acid)
- BIBF1120 ethanesulfonate salt
- (Z)-Methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene
- 1H-Indole-6-carboxylic acid,2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]-phenylmethylene]-2-oxo-, methylester, (3Z)-, ethanesulfonate (1:1)
- 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, ethanesulfonate (1:1)
- Nintedanib
(Ofev)
- (Z)-methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethanesulfonate
- BIBF 1120 BIBF-1120
- BIBF1120; BIBF 1120 BIBF-1120; NINTEDANIB ESYLATE. NINTEDANIB ETHANESULFONATE SALT; INTEDANIB; BRAND NAME OFEV. VARGATEF.
- Brand name OFEV. Vargatef.
- Nintedanib esylate. Nintedanib ethanesulfonate salt
- Nintedanib Ethanesulfonate (Intedanib Ethanesulfonate)
- Nintedani
- NSC 116056
- Nintedanib ethanesulfonate
- Nintedanib esylate
- 6-Benzofuranpropanenitrile,β-oxo-
- methyl (Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethanesulfonate
- Intedanib|||BIBF 1120 (esylate)|||Nintedanib Ethanesulfonate Salt|||BIBF 1120
- Buprenorphine Impurity 24
- NINTEDANIB, ETHANESULFONATE SALT
- ニンテダニブエタンスルホン酸塩
- ニンテダニブエシラート
- ニンテダニブエタンスルホン酸塩 (JAN)
- エタンスルホン酸/(3Z)-2,3-ジヒドロ-3-[[[4-[メチル[(4-メチル-1-ピペラジニル)アセチル]アミノ]フェニル]アミノ]フェニルメチレン]-2-オキソ-1H-インドール-6-カルボン酸メチル
- エタンスルホン酸とメチル=(Z)-3-({4-[N-メチル-2-(4-メチルピペラジン-1-イル)アセトアミド]アニリノ}(フェニル)メチリデン)-2-オキソインドリン-6-カルボキシラートの1:1塩